Skip to main content

Boniva Side Effects

Generic name: ibandronate

Medically reviewed by Last updated on Feb 7, 2024.

Note: This document contains side effect information about ibandronate. Some dosage forms listed on this page may not apply to the brand name Boniva.

Applies to ibandronate: oral tablet. Other dosage forms:

Serious side effects of Boniva

Along with its needed effects, ibandronate (the active ingredient contained in Boniva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ibandronate:

More common

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking ibandronate:

Symptoms of overdose

Other side effects of Boniva

Some side effects of ibandronate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to ibandronate: intravenous kit, intravenous solution, oral tablet.


The most serious reported adverse reactions are anaphylactic reaction/shock, atypical fractures of the femur, osteonecrosis of the jaw, and ocular inflammation.

The most frequently reported adverse reactions are arthralgia and influenza-like symptoms, typically associated with the first dose, generally of short duration, mild, or moderate intensity.[Ref]


Very common (10% or more): Dyspepsia (up to 12%)

Common (1% to 10%): Diarrhea, tooth disorder, vomiting, gastritis, constipation, gastroenteritis abdominal pain, esophagitis, nausea, sore throat

Uncommon (0.1% to 1%): Hemorrhage, duodenal ulcer, dysphagia, dry mouth[Ref]


Very common (10% or more): Upper respiratory infection (up to 34%)

Common (1% to 10%): Bronchitis, pneumonia, pharyngitis, influenza, nasopharyngitis, asthma exacerbation

Uncommon (0.1% to 1%): Chest pain[Ref]


Very common (10% or more): Hypocalcemia

Postmarketing reports: Hypocalcemia[Ref]

Decreased renal calcium excretion may be accompanied by a fall in serum phosphate levels not requiring therapeutic measures. The serum calcium level may fall to hypocalcemic values.[Ref]


Very common (10% or more): Back pain (14%)

Common (1% to 10%): Pain in the extremity, myalgia, joint disorder, arthritis, arthralgia, localized osteoarthritis, muscle cramp

Postmarketing reports: Severe or incapacitating bone, join, or muscle pain (musculoskeletal pain); osteonecrosis of the jaw; atypical, low-energy, or low-trauma fractures of the femoral shaft; atypical subtrochanteric and diaphyseal femoral fractures[Ref]


Common (1% to 10%): Hypertension

Uncommon (0.1% to 1%): Phlebitis, thrombophlebitis[Ref]


Common (1% to 10%): Urinary tract infection, cystitis[Ref]


Common (1% to 10%): Increased gamma-glutamyl transpeptidase (GGT) levels[Ref]


Common (1% to 10%): Allergic reaction

Rare (less than 0.1%): Facial swelling/edema, urticaria

Postmarketing reports: Anaphylactic reaction/shock with fatalities, angioedema, bronchospasm, asthma exacerbations, rash, Stevens-Johnson syndrome, erythema multiforme, and dermatitis bullous[Ref]


Common (1% to 10%): Redness or swelling at the injection site[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, paraesthesia, dysgeusia (taste perversion)[Ref]


Combination of influenza-like illness and acute phase reaction has occurred. Influenza-like illness includes events reported as acute phase reaction or symptoms, including myalgia, arthralgia, fever, chills, fatigue, nausea, loss of appetite, and bone pain.[Ref]

Common (1% to 10%): Asthenia, vertigo, influenza-like illness, peripheral edema

Uncommon (0.1% to 1%): Malaise, pain[Ref]


Common (1% to 10%): Insomnia, depression[Ref]


Common (1% to 10%): Increased creatinine

Uncommon (0.1% to 1%): Azotemia (uremia)

Postmarketing reports: Acute renal failure[Ref]


Rash occurred in combination of rash pruritic, rash macular, rash papular, rash generalized, rash erythematous, dermatitis, dermatitis allergic, dermatitis medicamentosa, erythema and exanthema.[Ref]

Uncommon (0.1% to 1%): Pruritus, rash[Ref]


Uncommon (0.1% to 1%): Anemia, increased blood parathyroid hormone[Ref]


Postmarketing reports: Ocular inflammation, iritis, uveitis, episcleritis (in some cases, these events resolve only after this drug was discontinued)[Ref]

Frequently asked questions


1. (2005) "Product Information. Boniva (ibandronate)." Roche Laboratories

2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

3. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.